CYCN News and Press, Cyclerion Therapeutics Inc. From 06/10/22

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment dis...

Topline results to be shared during the clinical trial update platform session CHOP preclinical data demonstrates CY6463-induced functional improvement in zebrafish disease models CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYC...

Cyclerion Therapeutics press release (NASDAQ:CYCN): Q1 net loss was approximately $13.0 million for the first quarter of 2022, as compared to $13.4 million for the first quarter of 2021. Cash, cash equivalents, and restricted cash balance on Mar. 31, 2022 was approximately $41 million, as com...

Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-l...

Cyclerion Therapeutics Inc. (NASDAQ:CYCN) traded at a new 52-week high today of $21.89. So far today approximately 36.3 million shares have been exchanged, as compared to an average 30-day volume of 114,000 shares. Over the past year, Cyclerion Therapeutics Inc. has traded in a range of ...

Shares of Cyclerion Therapeutics Inc. (NASDAQ:CYCN) traded today at $21.89, eclipsing its 52-week high. So far today approximately 36.2 million shares have been exchanged, as compared to an average 30-day volume of 118,000 shares. In the past 52 weeks, shares of Cyclerion Therapeutics In...

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 20...

CAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patien...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch a...

CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimer&#x...